Identification of Genetic Variants Associated With Unexpected Infant Death Syndrome

Launched by NANTES UNIVERSITY HOSPITAL · Feb 5, 2024

Keywords

ClinConnect Summary

This clinical trial is looking into the genetic causes of Sudden Infant Death Syndrome (SIDS), also known as sudden unexplained infant death. The researchers want to find out if certain genes or genetic changes can be linked to these tragic events. To do this, they will study the DNA of families who have experienced the unexpected death of an infant between 0 and 2 years old. The study will take place at multiple centers, and they are currently recruiting participants.

To be eligible, a child must have died unexpectedly within the specified age range and be part of a specific registry in France. Their biological parents, who are also invited to participate, need to agree to provide blood samples for testing. It's important to note that children with known genetic conditions at the time of death will not be included in the study. By participating, families can contribute to important research that may help improve understanding of SIDS and potentially lead to new findings that can prevent future cases.

Gender

ALL

Eligibility criteria

• • Child Inclusion Criteria
• • Death of a child between 0 and 2 years of age due to sudden unexpected death in infant
• • Child included in the French SUDI registry with effective participation in the biocollection
• • Children who also meet the inclusion criteria for the BIOMINRISK-NEUROBIO (axis 2) and BIOMINRISK-RADIO-ANAT (axis 3) studies in the overall BIOMINRISK project.
• • Parents Inclusion Criteria
• • Biological parents of the child included in the BIOMINRISK study
• • Parents who have both signed the consent form for blood collection and inclusion of their samples in the biocollection
• • parents beneficiaries of a social security or similar scheme
• Child Exclusion Criteria:
• • Presence of a known metabolic, genetic or syndromic pathology at the time of death
• Parents Exclusion Crtiteria:
• • Parent under guardianship
• • Presence of a known metabolic, genetic or syndromic pathology